Occudo Quantitative Strategies LP Purchases New Position in Natera, Inc. (NASDAQ:NTRA)

Occudo Quantitative Strategies LP bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 4,942 shares of the medical research company's stock, valued at approximately $782,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NTRA. OMERS ADMINISTRATION Corp boosted its stake in shares of Natera by 53.7% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 6,300 shares of the medical research company's stock valued at $997,000 after purchasing an additional 2,200 shares in the last quarter. Maven Securities LTD purchased a new stake in shares of Natera in the 4th quarter valued at $348,000. Miura Global Management LLC purchased a new stake in shares of Natera in the 4th quarter valued at $3,958,000. Lazard Asset Management LLC boosted its stake in shares of Natera by 22.0% in the 4th quarter. Lazard Asset Management LLC now owns 3,052 shares of the medical research company's stock valued at $482,000 after purchasing an additional 551 shares in the last quarter. Finally, LMR Partners LLP boosted its stake in shares of Natera by 515.4% in the 4th quarter. LMR Partners LLP now owns 20,209 shares of the medical research company's stock valued at $3,199,000 after purchasing an additional 16,925 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 6,000 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total value of $859,740.00. Following the sale, the insider now directly owns 143,768 shares in the company, valued at approximately $20,600,516.72. The trade was a 4.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 6,980 shares of Natera stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $150.10, for a total value of $1,047,698.00. Following the completion of the transaction, the chief executive officer now directly owns 185,182 shares of the company's stock, valued at approximately $27,795,818.20. This represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 152,436 shares of company stock worth $22,019,079 in the last quarter. Company insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of several analyst reports. Morgan Stanley increased their price target on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Piper Sandler increased their price target on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Thursday. Guggenheim increased their price target on shares of Natera from $170.00 to $200.00 and gave the company a "buy" rating in a research report on Friday, January 17th. The Goldman Sachs Group increased their price target on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Finally, UBS Group increased their price target on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Natera has an average rating of "Moderate Buy" and an average price target of $182.12.

Natera Stock Performance

Shares of NASDAQ NTRA traded up $3.19 during midday trading on Friday, reaching $152.59. 911,043 shares of the stock were exchanged, compared to its average volume of 1,386,529. The firm has a market cap of $20.84 billion, a price-to-earnings ratio of -86.70 and a beta of 1.79. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00. The firm has a 50-day simple moving average of $148.71 and a two-hundred day simple moving average of $156.51. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same quarter last year, the company earned ($0.56) EPS. The business's revenue was up 36.5% on a year-over-year basis. As a group, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.